Picture of Divi's Laboratories logo

DIVISLAB — Divi's Laboratories News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

India's Divi's Labs falls on US court ruling for heart drug

** Shares of Divi's Laboratories  DIVI.NS  settle down 2.6%
6,096.20 rupees, their worst day since mid-August
    ** DIVI second-biggest pct loser among pharma stocks
 .NIPHARM  which is up 0.2%
    ** Novartis  NOVN.S  failed to persuade U.S. court on
Wednesday to halt generic version of its blockbuster heart drug
Entresto
    ** Divi's Labs supplies active pharmaceutical ingredients
for Entresto
    ** Stock had dropped 4% in mid-August when Novartis lost
initial bid to block generic version of Entresto
    ** DIVI among 11 stocks on 20-member pharma index rated
"hold", rest rated "buy" or higher  - LSEG data
    ** Stock up ~56% YTD vs pharma index's 34% gain

 (Reporting by Nandan Mandayam in Bengaluru)
 ((Nandan.Mandayam@thomsonreuters.com; Mobile: +91 9591011727;))

Recent news on Divi's Laboratories

See all news